Oral bropirimine immunotherapy of rodent prostate cancer
Sarosdy, M.F.
European Urology 31(Suppl): 5-9
1997
ISSN/ISBN: 0302-2838 PMID: 9076480 Document Number: 482313
Objective: Bropirimine is an oral immunostimulant found to have efficacy in human transitional cell carcinoma in situ following the initial discovery of its antitumor activity against the murine bladder cancer MBT-2. To determine if bropirimine might have activity in prostate cancer, it was tested against two rodent prostate cancer cell lines in vivo. Methods: Tumors resulted from subcutaneous injection of PAIII and Dunning MAT-LyLu rodent prostate cancer cells. Bropirimine was given at 250 mg/kg orally on different schedules, and tumor volume and survival were recorded. Results: In the PAIII model, bropirimine prevented growth when given the day of tumor injection, and 95% of advanced tumors regressed completely when start of therapy was delayed. Bropirimine also caused growth inhibition and prolongation of survival in the MAT-LyLu model. Conclusions: Bropirimine immunotherapy is very effective in vivo against the PAIII cell line, and it has significant growth inhibition against the Dunning MAT-LyLu cell line.